We have been fortunate to participate in a study with Boehringer-Ingelheim using an IL-36 inhibitor for palmoplantar pustulosis (PPP). Patients on study have seen some excellent results. Hopefully this is an indication of how successful therapies of the future will be. This study has been on adult patients with PPP present for at least 3 months, and a minimum of 10 pustules. This study also featured a long term extension, where all patients continue to receive medication.
Unfortunately this study is no longer recruiting new patients, however, if you would like more information the clinical trial number is NCT04015518 at clinicaltrials.gov.